Mitchell Duffy

The companies drug screening platform is can be used by scientists performing research related to dugdrug discovery and the mechanisms of actionsaction underlying the effectiveness of drugs. The drug screening platform provides time series profiling of drug compounds using RNA-profiling technology to gain insight into how thousands of genes are interacting within the human body. The company thanthen uses machine learning algorithms to analyze the time series profile to discover causal signalling networks, which can give researchers insight into the underlying mechanisms of action for their drugs, and help them predict about how a certain drug will affect a patient.

Uses AI to assess the correct concrete mix for a given application. This reduces the use of costly and climate damaging cement while fulfilling design requirements.

Lesan was created to bring wider internet accessibility through translation to the next billion people.

Initially focusing on Ethiopic languages, Lesan will translate the web for Amharic and Tigrinya.

InGeneron seperates patient regenerative cells, adipose-derived regenerative cells (ADRCs) for research and veterinary use.

Voice powered lab assistant and electronic lab journal. LabTwin manages processes in both research and GMP manufacturing.

Currently the company focuses on analyzing the vaginal microbiome.

Nebula tokens are the currency used on the nebula network. Nebula tokens can be used to as payment to order genome sequencing for an individual. They are also the currency data buyers will use in order to purchase access to the genomic and phenotypic data available from individuals whose genomes are stored with Nebula.

Nebula tokens are the currency used on the nebula network. Nebula tokens can be used to as payment to order genome sequencing for an individual. They are also the currency data buyers will use in order to purchase access to the genomic and phenotypic data available from individuals whose genomes are stored with Nebula

Deep Genomics uses neural networks to analyze genomic data, allowing scientists to identify the genes that cause diseases and develop drugs that deal with them. It has also specialized in finding elusive and less direct disease triggers in a person’s genome. Deep learning can identify patterns in DNA that might contribute to diseases such as spinal muscular atrophy and nonpolyposis colorectal cancenonpolyposis colorectal cancer and nonpolyposis colorectal cancer that might contribute to diseases such as spinal muscular atrophy and nonpolyposis colorectal cancer can identify patterns in DNA that might contribute to diseases such as spinal muscular atrophy and nonpolyposis colorectal cancer.

On November 18th, 2015 raised $3,700,000 in seed funding from True Ventures, Bloomberg Beta, and 11.2 Capital, and 11.2 Capital.